News stories about Motus GI (NASDAQ:MOTS) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Motus GI earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.1220430585252 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several research analysts have recently weighed in on the stock. Oppenheimer assumed coverage on shares of Motus GI in a report on Monday, March 12th. They set an “outperform” rating and a $7.00 price objective on the stock. Piper Jaffray assumed coverage on shares of Motus GI in a report on Sunday, March 11th. They set an “overweight” rating and a $7.00 price objective on the stock.
Shares of MOTS stock traded up $0.09 during trading hours on Monday, hitting $4.57. 8,681 shares of the company were exchanged, compared to its average volume of 55,541. The firm has a market cap of $69.78 and a P/E ratio of -3.57. Motus GI has a 1 year low of $3.75 and a 1 year high of $5.30.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Motus GI (MOTS) Share Price” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/04/02/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-motus-gi-mots-share-price.html.
About Motus GI
Motus GI Holdings, Inc, a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.